Lasa Supergenerics enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


23.4	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.3	0.3	0.3	0.6	0.8
9.7	9.7	2.6	22.1	0.0
32.9	—	—	—	—
9.5	9.5	2.3	21.5	−0.8
₹6.56	—	—	—	—

59.4	59.4	86.3	119	118
16.4%	16.4%	3.0%	18.6%	0.0%
0.30×	—	—	—	—

5.17×	—	—	—	—
−3.77×	—	—	—	—
−2.23×	—	—	—	—
6.4	25.1	142	104	130
−8.7	−28.4	6.3	2.2	−6.6
−14.7	−34.4	−6.0	−8.5	−20.0
—	−22.8	−2.8	2.1	−33.5
−22.8	−22.8	−2.8	1.5	−38.3
—	−22.8	−3.5	1.5	−38.7
—	0.0	0.0	0.7	4.8

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health

₹ CrorePeersMANGALAM BIOFILCHEM ORTINGLOBE VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹23.4 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	23.4
- Cash, Equiv & ST Investments	0.8	0.6	0.3	0.3	0.3
+ Total Debt	0.0	22.1	2.6	9.7	9.7
Enterprise Value	—	—	—	—	32.9
Net Debt (memo)	-0.8	21.5	2.3	9.5	9.5
EV per Share	—	—	—	—	6.56

Total Capital	118.3	118.8	86.3	59.4	59.4
Total Debt/Total Capital	0.00	18.59	2.98	16.42	16.42
Total Debt/EV	—	—	—	—	0.30

EV/Sales	—	—	—	—	5.17
EV/EBITDA	—	—	—	—	-3.77
EV/EBIT	—	—	—	—	-2.23
Reference Items — Trailing FY Values
Sales	129.6	104.3	142.4	25.1	6.4
EBITDA	-6.6	2.2	6.3	-28.4	-8.7
EBIT	-20.0	-8.5	-6.0	-34.4	-14.7
Operating Cash Flow	-33.5	2.1	-2.8	-22.8	—
Free Cash Flow	-38.3	1.5	-2.8	-22.8	-22.8
FCFF (free cash flow to the firm)	-38.7	1.5	-3.5	-22.8	—
Capital Expenditure	4.8	0.7	0.0	0.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.